Liraglutide provided greater reductions in HbA1c and fasting glucose than exenatide, while exenatide had a stronger effect on post-meal blood sugar — both also promoting weight loss and modest blood pressure improvements.
Liraglutide > exenatide for HbA1cHead-to-head trials showed liraglutide achieved greater improvements in HbA1c and fasting glucose, while exenatide better controlled post-meal blood sugar
What the researchers found
Both exenatide and liraglutide improved glycemic control as monotherapy and in combination with oral agents, providing additive effects in dual and triple therapy regimens. In head-to-head clinical trials, liraglutide achieved greater reductions in HbA1c and fasting plasma glucose, while exenatide had greater effects on postprandial glucose levels.
Both agents demonstrated statistically significant weight reduction and small beneficial effects on blood pressure, with unchanged lipid profiles. The review positioned GLP-1 receptor agonists as a treatment option that could address multiple cardiometabolic parameters beyond glycemic control alone.
Why it matters
This review captures the GLP-1 receptor agonist class at a pivotal early moment — when only two agents existed and their place in diabetes treatment algorithms was still being established. The clinical advantages identified here (glycemic control plus weight loss plus blood pressure benefits) foreshadowed the class's massive expansion into obesity treatment and cardiovascular protection over the following decade.
How the study worked
Narrative review of clinical trial data for exenatide and liraglutide in type 2 diabetes, covering efficacy (glycemic control, weight, blood pressure, lipids), safety, contraindications, and placement in treatment algorithms.
What this study cannot tell us
As a 2012 review, this covers only first-generation GLP-1 agonists (exenatide and liraglutide) and does not reflect the dramatically expanded evidence base and newer agents available today. The review is by a single author without systematic methodology. Long-term cardiovascular outcome data, which later became the class's strongest selling point, were not yet available.
How to read the evidence
This is a narrative review of clinical trial data by a single author. While it summarizes evidence from randomized trials, the review itself is not a systematic review or meta-analysis, and the evidence base has been vastly superseded since publication.
When this study was published
Published in 2012, this review is now significantly dated. The GLP-1 agonist field has expanded dramatically with newer, more potent agents and major cardiovascular and weight management outcome trials. It remains useful as a historical snapshot of the class's early clinical positioning.
The bigger picture
This 2012 review represents the beginning of the GLP-1 agonist era. The class has since exploded to include semaglutide, tirzepatide, and others, with indications expanding from diabetes to obesity, cardiovascular disease, kidney disease, and even neurological conditions. The weight loss and blood pressure benefits noted early on turned out to be just the tip of the iceberg.
Questions still open
- How do the newer GLP-1 agonists like semaglutide compare to the first-generation agents reviewed here in terms of efficacy and side effects?
- Has the early promise of blood pressure reduction with GLP-1 agonists been confirmed in cardiovascular outcome trials?
- What role do GLP-1 agonists play in current treatment algorithms compared to their initial positioning in 2012?
Common questions
What is the difference between exenatide and liraglutide?
How has the GLP-1 drug class evolved since this 2012 review?
Read the original research
Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
The Journal of the American Osteopathic Association, 112(1 Suppl 1), S7-15
Citation
Spellman, Craig W. (2012). Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.. The Journal of the American Osteopathic Association, 112(1 Suppl 1), S7-15.